@article{7a7a236eec054c1bba7749fac733851a,
title = "Prevalence and characteristics of individuals with preserved ratio impaired spirometry (Prism) and/or impaired lung function in japan: The ocean study",
abstract = "Purpose: Many individuals with obstructive airway disease (OAD), including chronic obstructive pulmonary disease (COPD) and asthma, remain undiagnosed, despite the potential for reducing disease burden through early detection and treatment. OCEAN aimed to determine the prevalence of, and characteristics associated with, impaired lung function in a Japanese population, with the goal of improving strategies for early OAD detection. Methods: OCEAN was an observational, cross-sectional study in sequentially recruited Japanese individuals ≥40 years of age undergoing routine health examinations. Participants completed screening questionnaires and spirometry testing. Airflow limitation was defined as forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) <0.7 by pre-bronchodilator spirometry. Preserved ratio impaired spirometry (PRISm) was defined as FEV1/FVC ≥0.7 and FEV1 <80% predicted. The primary endpoint was prevalence of spirometry-based airflow limitation and PRISm. The characteristics of study participants were reported as secondary endpoints. Results: Overall, 2518 individuals were included; 79% were <60 years of age (mean 52.0 years). Airflow limitation and PRISm were observed in 52 (2.1%) and 420 (16.7%) partici-pants, respectively. FEV1 in the PRISm group was between that in the no airflow limitation/ PRISm and airflow limitation groups, FVC was similar in the PRISm and airflow limitation groups. The PRISm group had higher mean body mass index and a higher proportion of comorbid metabolic disease compared with the airflow limitation group. The prevalence of airflow limitation and PRISm was highest among current smokers (3.9% and 21.3%, respectively) versus former or never smokers. Conclusion: A significant proportion of Japanese individuals <60 years of age attending their annual health examination had impaired lung function (airflow limitation and PRISm); prevalence was highest among current smokers. These findings support screening of current or former smokers ≥40 years of age using patient-reported questionnaires to inform the need for spirometry to confirm an OAD diagnosis.",
keywords = "Airflow limitation, CAAT, CAPTURE, COPD-Q, Japan, PRISm",
author = "Toshihiko Kaise and Eishin Sakihara and Kentaro Tamaki and Hiroaki Miyata and Norimichi Hirahara and Oksana Kirichek and Ryosuke Tawara and Shoko Akiyama and Masayuki Katsumata and Mei Haruya and Takeo Ishii and Simard, {Edgar P.} and Miller, {Bruce E.} and Ruth Tal-Singer",
note = "Funding Information: This study was funded by GSK (Study HO-18-19229/ 209243). The funders of the study had a role in study design, data analysis, data interpretation, and writing of the report. Funding Information: The CAPTURE questionnaire was provided by Cornell University, Ithaca, NY, USA, and translations of the CAPTURE and CAAT questionnaires were provided by AstraZeneca, Cambridge, UK. Editorial support in the form of preparation of the first draft based on input from all authors, and collation and incorporation of author feed-back to develop subsequent drafts, was provided by Fiona Woodward, PhD, CMPP and Alexandra Berry, MSc, of Fishawack Indicia Ltd., UK, part of Fishawack Health, and was funded by GlaxoSmithKline (GSK). The abstract of this paper was presented at the American Thoracic Society Annual Meeting 2020 as a poster presentation with interim findings. The poster{\textquoteright}s abstract was published in “Poster Abstracts” in American Journal of Respiratory and Critical Care Medicine 2020;201:A5077: 10.1164/ ajrccm-conference.2020.201.1_MeetingAbstracts.A5077. This study was funded by GSK (Study HO-18-19229/ 209243). The funders of the study had a role in study design, data analysis, data interpretation, and writing of the report. Funding Information: The CAPTURE questionnaire was provided by Cornell University, Ithaca, NY, USA, and translations of the CAPTURE and CAAT questionnaires were provided by AstraZeneca, Cambridge, UK. Editorial support in the form of preparation of the first draft based on input from all authors, and collation and incorporation of author feedback to develop subsequent drafts, was provided by Fiona Woodward, PhD, CMPP and Alexandra Berry, MSc, of Fishawack Indicia Ltd., UK, part of Fishawack Health, and was funded by GlaxoSmithKline (GSK). The abstract of this paper was presented at the American Thoracic Society Annual Meeting 2020 as a poster presentation with interim findings. The poster{\textquoteright}s abstract was published in “Poster Abstracts” in American Journal of Respiratory and Critical Care Medicine 2020;201:A5077: 10.1164/ Publisher Copyright: {\textcopyright} 2021 Kaise et al.",
year = "2021",
doi = "10.2147/COPD.S322041",
language = "English",
volume = "16",
pages = "2665--2675",
journal = "International Journal of COPD",
issn = "1176-9106",
publisher = "Dove Medical Press Ltd.",
}
